Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on June 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA orphan drug designations granted to alixorexton.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA orphan drug designations granted to alixorexton
- Designations support development for rare diseases and may provide regulatory incentives
- Press release dated June 15, 2026 contains the substantive announcement
Item 8.01 · Other Events
- FDA orphan drug designation for alixorexton in idiopathic hypersomnia
- European Commission orphan designation for narcolepsy
- Regulatory recognition supports development in two sleep-disorder indications
- Orphan status may provide development incentives and potential market exclusivity upon approval
Item EX-99.1 · Exhibit EX-99.1
- FDA granted orphan designation for alixorexton in idiopathic hypersomnia, enabling development incentives and potential seven-year U.S. exclusivity if approved
- European Commission granted orphan designation for narcolepsy, potentially supporting regulatory assistance and up to 10 years’ EU exclusivity if approved
- Alixorexton advancing in phase 3 Brilliance trials for NT1 and NT2 and phase 2 Vibrance-3 for idiopathic hypersomnia
- Prior FDA Breakthrough Therapy designation for NT1 strengthens regulatory significance, but approval and commercial value remain dependent on clinical outcomes
- IH affects an estimated 40,000 people in the U.S., highlighting a defined rare-disease opportunity for Alkermes’s pipeline candidate
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.